Synergistic Enhancement of Cisplatin Anticancer Efficacy by Photobiomodulation Therapy: A Systematic Review.

IF 1.8 Q2 SURGERY

Photobiomodulation, photomedicine, and laser surgery Pub Date : 2025-10-01 Epub Date: 2025-09-04 DOI:10.1177/25785478251372762

Emad Jafarzadeh, Fereshtehsadat Jalali, Jaber Zafari, Fatemeh Fakhari

{"title":"Synergistic Enhancement of Cisplatin Anticancer Efficacy by Photobiomodulation Therapy: A Systematic Review.","authors":"Emad Jafarzadeh, Fereshtehsadat Jalali, Jaber Zafari, Fatemeh Fakhari","doi":"10.1177/25785478251372762","DOIUrl":null,"url":null,"abstract":"Introduction: Cisplatin (Cis), a key cancer chemotherapy drug, faces limitations such as dose-dependent side effects and resistance. Photobiomodulation therapy (PBMT) shows promise as an adjuvant therapy to enhance Cis efficacy and reduce side effects. Methods: A systematic review was conducted to evaluate the combined effects of PBMT and Cis on various cancers. After searching five databases using relevant keywords, nine studies were included, encompassing both in vitro and in vivo models. Results: Most in vitro studies showed a synergistic effect, with enhanced cancer cell inhibition, apoptosis induction, and reduced cell viability compared with Cis alone. The animal model confirmed these findings, showing PBMT mitigated Cis-induced acute renal failure. Conclusion: Mechanistically, PBMT may increase reactive oxygen species generation, cytochrome c release, modulate cellular metabolism, and involve the miR-124/STAT3 signaling pathway. Combining PBMT with Cis appears to be a safe and effective cancer treatment strategy, synergistically inhibiting cancer cell growth and reducing side effects. Further clinical trials are needed to validate these findings.","PeriodicalId":94169,"journal":{"name":"Photobiomodulation, photomedicine, and laser surgery","volume":" ","pages":"468-474"},"PeriodicalIF":1.8000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Photobiomodulation, photomedicine, and laser surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25785478251372762","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Cisplatin (Cis), a key cancer chemotherapy drug, faces limitations such as dose-dependent side effects and resistance. Photobiomodulation therapy (PBMT) shows promise as an adjuvant therapy to enhance Cis efficacy and reduce side effects. Methods: A systematic review was conducted to evaluate the combined effects of PBMT and Cis on various cancers. After searching five databases using relevant keywords, nine studies were included, encompassing both in vitro and in vivo models. Results: Most in vitro studies showed a synergistic effect, with enhanced cancer cell inhibition, apoptosis induction, and reduced cell viability compared with Cis alone. The animal model confirmed these findings, showing PBMT mitigated Cis-induced acute renal failure. Conclusion: Mechanistically, PBMT may increase reactive oxygen species generation, cytochrome c release, modulate cellular metabolism, and involve the miR-124/STAT3 signaling pathway. Combining PBMT with Cis appears to be a safe and effective cancer treatment strategy, synergistically inhibiting cancer cell growth and reducing side effects. Further clinical trials are needed to validate these findings.

查看原文本刊更多论文

光生物调节疗法协同增强顺铂抗癌疗效的系统综述。

导读：顺铂（Cisplatin, Cis）是一种重要的癌症化疗药物，但存在剂量依赖和耐药等局限性。光生物调节疗法（PBMT）作为一种辅助治疗有望提高顺式Cis的疗效和减少副作用。方法：系统评价PBMT和Cis联合治疗多种癌症的效果。使用相关关键词检索5个数据库，纳入9项研究，包括体外和体内模型。结果：大多数体外研究显示协同作用，与单独使用Cis相比，具有增强的癌细胞抑制、诱导凋亡和降低细胞活力的作用。动物模型证实了这些发现，显示PBMT减轻顺式诱导的急性肾功能衰竭。结论：从机制上看，PBMT可能增加活性氧的产生、细胞色素c的释放、调节细胞代谢，并参与miR-124/STAT3信号通路。PBMT联合Cis似乎是一种安全有效的癌症治疗策略，协同抑制癌细胞生长并减少副作用。需要进一步的临床试验来验证这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Photobiomodulation, photomedicine, and laser surgery

CiteScore

4.10

自引率

0.00%

发文量

期刊介绍： Photobiomodulation, Photomedicine, and Laser Surgery Editor-in-Chief: Michael R Hamblin, PhD Co-Editor-in-Chief: Heidi Abrahamse, PhD